NXTC
NextCure, Inc. Common Stock
stockNASDAQ
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 5.08 | 2026-09-28 | +0.98% | 3.178 |
| 1M | 7.82 | 2026-09-04 | -34.40% | -1.774 |
| 3M | 2.07 | 2026-07-06 | +147.83% | 5.819 |
| 6M | 11.03 | 2026-04-06 | -53.49% | 2.618 |
| 1Y | 5.84 | 2025-10-03 | -12.16% | 1.955 |
| 2Y | 16.20 | 2024-10-04 | -68.33% | — |
| 5Y | 94.08 | 2021-10-04 | -94.55% | 0.802 |
NextCure, Inc. Common Stock (NASDAQ:NXTC) stock price today is $5.13, and today's volume is 63,333. NXTC is up 3.427% today. The 30 day average volume is 99,794. NXTC market cap is $23.48M with 4.58M shares outstanding.